Xenon Pharmaceuticals Inc. (Nasdaq: XENE) filed a Form 8-K on November 9, 2026, reporting financial results for the third quarter ended September 30, 2026, and providing a business update.
The company announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for azetukalner in September 2026, targeting focal seizures. This submission follows the completion of enrollment in the Phase 3 X-NOVA2 study for major depressive disorder, with topline data expected in December 2026.
Xenon also highlighted progress in its pain portfolio. Positive Phase 1 data for XEN1701 (targeting Na V 1.7) and XEN1120 (targeting K V 7) were presented at the IASP World Congress on Pain. Based on these results, the company plans to initiate Phase 2 proof-of-concept studies in acute pain in the first half of 2027.
Regarding its financial position, Xenon reported cash, cash equivalents, and marketable securities of $1,153.5 million as of September 30, 2026. This represents a significant increase from $586.0 million at the end of 2025. The company stated that, based on current operating plans, it anticipates having sufficient cash to fund operations into 2029.
Research and development expenses for the third quarter of 2026 were $95.6 million, compared to $77.1 million in the same period in 2025. General and administrative expenses were $24.4 million for the quarter, compared to $19.3 million in the prior year. The company reported a net loss of $110.4 million for the quarter.
